Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × etirinotecan pegol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 Breast Neoplasms 2 Oligodendroglioma 1 Neoplasms 1 Neoplasm Metastasis 1 Malignant Solid Tumor 1 Glioblastoma 1 Colorectal Neoplasms 1 Carcinoma 1 Astrocytoma 1 Advanced Cancer 1

Interventions

Cisplatin 46 Carboplatin 43 pembrolizumab 39 Paclitaxel 38 Gemcitabine 27 Radiotherapy 19 Pemetrexed 19 Magnetic Resonance Spectroscopy 18 Radiotherapy, Intensity-Modulated 17 Docetaxel 17 Cetuximab 16 Specimen Handling 15 Nivolumab 15 Cyclophosphamide 14 durvalumab 13 Fluorouracil 13 Sorafenib 10 Bevacizumab 10 130-nm albumin-bound paclitaxel 10 Sunitinib 9 Platinum 9 osimertinib 8 Radiation 8 Oxaliplatin 8 Irinotecan 8 Everolimus 8 Capecitabine 8 1,2-diaminocyclohexaneplatinum II citrate 8 Ipilimumab 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡